title: Prognosis of Alzheimer's disease today: a two-year prospective study in 686 patients from the REAL-FR Study.
abstract: BACKGROUND
  The aim of the present study was to describe the long-term evolution of Alzheimer's disease (AD) in a prospective cohort of patients under treatment with a close follow-up.
  
  
  METHODS
  Six hundred eighty-six AD patients from the French Network on AD (REAL-FR) were followed up and assessed every 6 months for 2 years. Cognitive, functional, behavioral, nutritional, and global status were evaluated by using Mini-Mental State Examination (MMSE), cognitive subscale of AD Assessment Scale (ADAS-cog), Activities of Daily Living scale (ADL), Neuropsychiatric Inventory (NPI), Mini-Nutritional Assessment (MNA), and Clinical Dementia Rating (CDR).
  
  
  RESULTS
  There were 85.13% of patients who were specifically treated for AD during their participation in the study. We observed significant changes (P < .0001) on MMSE, -4.57 +/- 0.23; ADAS-cog, 7.11 +/- 0.41; ADL, -1.32 +/- 0.07; NPI, 2.94 +/- 0.77; MNA, -0.81 +/- 0.17; and sum of boxes of the CDR (CDR-SB), 4.17 +/- 0.17. After 2 years, 10.79% (95% confidence interval [CI], 8.47 to 13.11) of the patients evolved twice as rapidly as the mean of the whole cohort on MMSE (loss, > or =9 points), 65.89% (95% CI, 62.34 to 69.44) reported a loss of 3 to 9 points, and 23.32% (95% CI, 20.16 to 26.46) were stable or improved (loss of -2 points maximum). Annual incidences for institutionalization, hospitalization, and death were 11.84% (95% CI, 9.76 to 13.92), 26.13% (95% CI, 22.52 to 29.74), and 5.95% (95% CI, 4.56 to 7.34), respectively.
  
  
  CONCLUSIONS
  In a recent large AD cohort mostly under treatment, AD evolution appeared to be variable, with high incidences for death or institutionalization and with 11.84% of the patients exhibiting a rapid cognitive decline, whereas one fourth of the cohort appeared in relatively stable condition, and two thirds had a moderate but significant evolution of the disease. More studies are needed to better understand these variations in patients' evolution.
authors.affiliation: Department of Internal Medicine and Clinical Gerontology, Centre Hospitalier Universitaire Purpan-Casselardit, Toulouse, France. cortes.fr@chu-toulouse.fr
authors.forename: Frédéric
authors.initials: F
authors.lastname: Cortes
authors.forename: Fati
authors.initials: F
authors.lastname: Nourhashémi
authors.forename: Olivier
authors.initials: O
authors.lastname: Guérin
authors.forename: Christelle
authors.initials: C
authors.lastname: Cantet
authors.forename: Sophie
authors.initials: S
authors.lastname: Gillette-Guyonnet
authors.forename: Sandrine
authors.initials: S
authors.lastname: Andrieu
authors.forename: Pierre-Jean
authors.initials: PJ
authors.lastname: Ousset
authors.forename: Bruno
authors.initials: B
authors.lastname: Vellas
mesh_terms: D000203:Activities of Daily Living; D000368:Aged; D000544:Alzheimer Disease / Q000503:physiopathology*; D018450:Disease Progression; D005260:Female; D006801:Humans; D008297:Male; D009483:Neuropsychological Tests; D015596:Nutrition Assessment; D011379:Prognosis; D011569:Psychiatric Status Rating Scales